1

SUPPORTING INFORMATION

cis-Semihydrogenation of alkynes with amine borane complexes catalyzed by gold nanoparticles under mild conditions

Eleni Vasilikogiannaki, Ioannis Titilas, Georgios Vassilikogiannakis and Manolis Stratakis*

Department of Chemistry, University of Crete, Voutes 71003 Iraklion, Greece stratakis@chemistry.uoc.gr

-	2-10	Experimental section
	11-37	¹ H and ¹³ C NMR spectra of products
	38-39	¹¹ B-MNR spectra of ammonia borane and its by-product after
		reduction

Table of contents

Experimental Section

List of alkynes used in our experiments



Substrates 1, 2, 3, 5, 9, 11, 12, 15, 19, 20, 23, 24, 25, 26, 27 and 28 are commercially available. Alkynes 6, 7, 8 and 10 were available from previous studies in our lab.¹ Substrate 4^2 was prepared by protection of 30 with TBDPSCl under standard silyl protection conditions, and 18 via benzylation of 3-butyn-1-ol. Internal alkynes 13,³ 14,⁴ 16,⁵ 17,⁶ 21⁷ and 22⁸ were prepared by treatment of the corresponding precursor terminal alkyne with *n*-BuLi (THF, 1.1 equiv, -78 °C, 1h) followed by quench with a suitable electrophile (butyraldehyde for 13 and 16, cyclohexanone for 14, acetone for 17 and ClCOOEt for 21-22). See the general synthetic Scheme below:



Typical procedure of the Au/TiO₂-catalyzed semireduction of alkynes

To a vial containing *p*-methoxyphenylacetylene, **1** (0.053 g, 0.4 mmol) and 1 mL ethanol were added at room temperature Me₂NHBH₃ (12 mg, 0.2 mmol) and immediately after Au/TiO₂ (79 mg, 1.0 mol%). The Au content in catalyst is ~1 wt%. The reaction was monitored by TLC and GC, and after 30 min (100% conversion) the slurry was filtered under reduced pressure through a short pad of silica gel with the aid of ethanol (2-3 mL) to withhold the supported catalyst and inorganic salts. The filtrate was evaporated under vacuum to afford *p*-methoxystyrene, **1a** (50 mg, 94% yield).

Spectroscopic data of products

1-Methoxy-4-vinylbenzene (1a)⁹



¹H NMR (500 MHz, CDCl₃): 7.36 (d, J = 8.0 Hz, 2H), 6.87 (d, J = 8.0 Hz, 2H), 6.66 (dd, $J_1 = 17.0$ Hz, $J_2 = 10.5$ Hz, 1H), 5.61 (dd, $J_1 = 17.0$ Hz, $J_2 = 1.2$ Hz, 1H), 5.13 (dd, $J_1 = 10.5$ Hz, $J_2 = 1.2$ Hz, 1H), 3.81 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): 159.3, 136.2, 130.4, 127.4, 113.9, 111.5, 55.3.

N,*N*-Dimethyl-4-vinylaniline (3a)¹⁰



¹H NMR (300 MHz, CDCl₃): 7.33 (m, 2H), 6.72 (m, 2H), 6.66 (dd, $J_1 = 17.0$ Hz, $J_2 = 10.5$ Hz, 1H), 5.57 (dd, $J_1 = 17.0$ Hz, $J_2 = 1.2$ Hz, 1H), 5.05 (dd, $J_1 = 10.5$ Hz, $J_2 = 1.2$ Hz, 1H), 2.98 (s, 6H); ¹³C NMR (75 MHz, CDCl₃): 150.2, 136.6, 127.1, 126.3, 112.3, 109.3, 40.5.

tert-Butyl(2-methoxy-5-vinylphenoxy)dimethylsilane (4a)¹¹



¹H NMR (500 MHz, CDCl₃): 6.96-6.94 (m, 2H), 6.79 (d, J = 8.5 Hz, 1H), 6.60 (dd, $J_1 = 16.5$ Hz, $J_2 = 10.5$ Hz, 1H), 5.57 (dd, $J_1 = 16.5$ Hz, $J_2 = 1.0$ Hz, 1H), 5.11 (dd, $J_1 = 10.5$ Hz, $J_2 = 1.0$ Hz, 1H), 3.81 (s, 3H), 1.01 (s, 9H), 0.17 (s, 6H); ¹³C NMR (125 MHz, CDCl₃): 150.9, 145.0, 136.3, 130.8, 120.1, 118.3, 111.8, 111.6, 55.5, 25.7, 18.4, -4.6.

(Allyloxy)benzene (6a)⁹

¹H NMR (500 MHz, CDCl₃): 7.30-7.25 (m, 2H), 6.97-6.91 (m, 3H), 6.10-6.04 (m, 1H), 5.42 (dd, $J_1 = 16.5$ Hz, $J_2 = 1.0$ Hz, 1H), 5.29 (dd, $J_1 = 10.5$ Hz, $J_2 = 1.0$ Hz, 1H), 4.55 (d, J = 5.0 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃): 158.6, 133.3, 129.4, 120.8, 117.6, 114.7, 68.7.

(Allyloxy)(tert-butyl)diphenylsilane (7a)¹²

¹H NMR (500 MHz, CDCl₃): 7.72-7.69 (m, 4H), 7.45-7.37 (m, 6H), 5.98-5.91 (m, 1H), 5.39 (dd, $J_1 = 16.5$ Hz, $J_2 = 1.0$ Hz, 1H), 5.12 (dd, $J_1 = 10.5$ Hz, $J_2 = 1.0$ Hz, 1H), 4.22 (m,

2-(Allyloxy)tetrahydro-2H-pyran (8a)9

THPO 8a

¹H NMR (300 MHz, CDCl₃): 5.98-5.90 (m, 1H), 5.30 (qd, $J_I = 16.5$ Hz, $J_2 = 1.5$ Hz, 1H), 5.17 (qd, $J_I = 10.5$ Hz, $J_2 = 1.5$ Hz, 1H), 4.65 (dd, $J_I = 4.0$ Hz, $J_2 = 3.5$ Hz, 1H), 4.24 (tdd, $J_I = 13.0$ Hz, $J_2 = 5.5$ Hz, $J_3 = 1.5$ Hz, 1H), 3.99 (tdd, $J_I = 13.0$ Hz, $J_2 = 5.5$ Hz, $J_3 = 1.5$ Hz, 1H), 3.99 (tdd, $J_I = 13.0$ Hz, $J_2 = 5.5$ Hz, $J_3 = 1.5$ Hz, 1H), 3.97-3.85 (m, 1H), 3.53-3.49 (m, 1H), 1.89-1.82 (m, 1H), 1.76-1.70 (m, 1H), 1.64-1.50 (m, 4H); ¹³C NMR (75 MHz, CDCl₃): 134.7, 116.7, 97.9, 68.0, 62.2, 30.6, 25.4, 19.4.

tert-Butyl allylcarbamate (9a)⁹

¹H NMR (300 MHz, CDCl₃): 5.89-5.76 (m, 1H), 5.16 (dd, J_1 = 16.5 Hz, J_2 = 1.5 Hz, 1H), 5.09 (dd, J_1 = 11.0 Hz, J_2 = 1.5 Hz, 1H), 4.62 (br s, 1H, NH), 3.74 (br m, 2H), 1.44 (s, 9H); ¹³C NMR (75 MHz, CDCl₃): 155.8, 134.9, 115.7, 79.3, 43.0, 28.4.

Hex-5-en-1-yl acetate (10a)⁹



¹H NMR (500 MHz, CDCl₃): 5.73 (ddt, J_1 = 15.0 Hz, J_2 = 10.0 Hz, J_3 = 6.5 Hz, 1H), 5.01 (dd, J_1 = 15.0 Hz, J_2 = 1.0 Hz, 1H), 4.96 (dd, J_1 = 10.0 Hz, J_2 = 1.0 Hz, 1H), 4.06 (t, J = 6.5 Hz, 2H), 2.10-2.05 (m, 2H), 2.04 (s, 3H), 1.67-1.60 (m, 2H), 1.48-1.44 (m, 2H); ¹³C NMR (125 MHz, CDCl₃): 171.2, 138.3, 114.8, 64.4, 33.3, 28.0, 25.2, 21.0.

Hex-5-en-1-ol (11a)⁹



¹H NMR (300 MHz, CDCl₃): 5.72 (ddt, J_1 = 15.5 Hz, J_2 = 10.0 Hz, J_3 = 6.5 Hz, 1H), 5.02 (dd, J_1 = 15.5 Hz, J_2 = 1.0 Hz, 1H), 4.96 (dd, J_1 = 10.0 Hz, J_2 = 1.0 Hz, 1H), 3.65 (t, J = 6.5 Hz, 2H), 2.13-2.05 (m, 2H), 1.64-1.42 (m, 4H); ¹³C NMR (75 MHz, CDCl₃): 138.6, 114.6, 62.7, 33.4, 32.1, 25.0.

(Z)-Oct-2-en-1-ol (12a)¹³



¹H NMR (500 MHz, CDCl₃): 5.63-5.52 (m, 2H), 4.19 (d, J = 6.5 Hz, 2H), 2.09-2.04 (m, 2H), 1.39-1.24 (m, 6H), 0.89 (t, J = 8.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): 133.3, 128.3, 58.6, 31.4, 29.3, 27.4, 22.5, 14.0.

(Z)-Undec-5-en-4-ol $(13a)^3$



¹H NMR (300 MHz, CDCl₃): 5.52-5.32 (m, 2H), 4.45-4.40 (m, 1H), 2.13-1.98 (m, 2H), 1.62-1.24 (m, 10H), 0.92 (t, J = 7.5 Hz, 3H), 0.89 (t, J = 7.5 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): 132.6, 132.3, 67.5, 39.7, 31.5, 29.4, 27.6, 22.5, 18.6, 14.0, 14.0.

(Z)-1-(Hept-1-en-1-yl)cyclohexanol (14a)¹⁴



¹H NMR (300 MHz, CDCl₃): 5.45 (d, J = 10.5 Hz, 1H), 5.37 (td, $J_1 = 10.5$ Hz, $J_2 = 6.5$ Hz, 1H), 2.38-2.31 (m, 2H), 1.68-1.26 (m, 16H), 0.91 (t, J = 7.0 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): 135.9, 132.6, 72.4, 39.3, 31.6, 29.8, 28.5, 25.5, 22.6, 22.4, 14.0.

(Z)-3-Phenylprop-2-en-1-ol (15a)¹⁵

¹H NMR (300 MHz, CDCl₃): 7.38-7.20 (m, 5H), 6.58 (dd, $J_1 = 11.0$ Hz, $J_2 = 1.5$ Hz, 1H), 5.88 (td, $J_1 = 11.0$ Hz, $J_2 = 6.5$ Hz, 1H), 4.44 (dd, $J_1 = 6.5$ Hz, $J_2 = 1.5$ Hz, 2H); ¹³C NMR (75 MHz, CDCl₃): 136.5, 131.1, 131.1, 128.8, 128.2, 127.2, 59.7.

(*Z*)-1-Phenylhex-1-en-3-ol (16a)¹⁶



¹H NMR (300 MHz, CDCl₃): 7.37-7.22 (m, 5H), 6.56 (d, J = 11.5 Hz, 1H), 5.67 (dd, $J_1 = 11.5$ Hz, $J_2 = 8.5$ Hz, 1H), 4.63-4.55 (m, 1H), 1.67-1.36 (m, 4H), 0.92 (t, J = 7.5 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): 136.7, 134.7, 131.0, 128.7, 128.3, 127.2, 67.6, 39.8, 18.6, 14.0.

(Z)-2-Methyl-4-phenylbut-3-en-2-ol (17a)¹⁶



¹H NMR (300 MHz, CDCl₃): 7.37-7.21 (m, 5H), 6.46 (d, J = 13.0 Hz, 1H), 5.76 (d, J = 13.0 Hz, 1H), 1.36 (s, 6H); ¹³C NMR (75 MHz, CDCl₃): 139.3, 137.5, 129.0, 128.1, 127.8, 126.9, 72.1, 31.2.

((But-3-en-1-yloxy)methyl)benzene (18a)¹⁷



¹H NMR (500 MHz, CDCl₃): 7.36-7.27 (m, 5H), 5.89-5.81 (m, 1H), 5.11 (d, J = 17.0 Hz, 1H), 5.05 (d, J = 11.0 Hz, 1H), 4.53 (s, 2H), 3.54 (t, J = 7.0 Hz, 2H), 2.41-2.37 (m, 2H); ¹³C NMR (125 MHz, CDCl₃): 138.4, 135.3, 128.3, 127.6, 127.5, 116.3, 72.9, 69.6, 34.2.

(Z)-Ethyl 3-phenylacrylate (20a)¹⁸



¹H NMR (300 MHz, CDCl₃): 7.60-7.56 (m, 2H), 7.39-7.32 (m, 3H), 6.95 (d, *J* = 13.0 Hz, 1H), 5.95 (d, *J* = 13.0 Hz, 1H), 4.18 (q, *J* = 7.0 Hz, 2H), 1.25 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): 166.2, 142.9, 134.9, 129.6, 128.9, 128.0, 119.9, 60.3, 14.1.

(Z)-Ethyl oct-2-enoate $(21a)^{19}$



¹H NMR (300 MHz, CDCl₃): 6.22 (td, $J_1 = 11.5$ Hz, $J_2 = 7.5$ Hz, 1H), 5.80 (td, $J_1 = 11.5$ Hz, $J_2 = 1.5$ Hz, 1H), 4.16 (q, J = 7.0 Hz, 2H), 2.68-2.60 (m, 2H), 1.50-1.39 (m, 2H), 1.28 (t, J = 7.0 Hz, 3H), 1.35-1.22 (m, 4H), 0.88 (t, J = 7.0 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): 166.5, 150.7, 119.6, 59.7, 31.5, 28.9, 28.7, 22.5, 14.3, 14.0.

(Z)-Ethyl 4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-enoate (22a)²⁰

¹H NMR (300 MHz, CDCl₃): 6.41 (td, $J_I = 11.5$ Hz, $J_2 = 7.5$ Hz, 1H), 5.81 (td, $J_I = 11.5$ Hz, $J_2 = 2.5$ Hz, 1H), 4.80 (ddd, $J_I = 17.0$ Hz, $J_2 = 5.0$ Hz, $J_3 = 2.5$ Hz, 1H), 4.67 (ddd, $J_I = 17.0$ Hz, $J_2 = 5.0$ Hz, $J_3 = 2.5$ Hz, 1H), 4.67 (ddd, $J_I = 17.0$ Hz, $J_2 = 5.0$ Hz, $J_3 = 2.5$ Hz, 1H), 4.64-4.62 (m, 1H), 4.14 (q, J = 7.0 Hz, 2H), 3.90-3.83 (m, 1H), 3.54-3.47 (m, 1H), 1.86-1.48 (m, 6H), 1.28 (t, J = 7.0 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): 166.0, 148.2, 119.3, 98.9, 62.7, 65.7, 62.5, 60.2, 30.6, 25.4, 19.6, 14.2. (*Z*)-**3-Phenylacrylonitrile (23a)**²¹



¹H NMR (300 MHz, CDCl₃): 7.83-7.79 (m, 2H), 7.46-7.43 (m, 3H), 7.13 (d, *J* = 12.0 Hz, 1H), 5.45 (d, *J* = 12.0 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): 148.7, 133.6, 131.0, 129.0, 128.9, 117.3, 95.1.

(Z)-1,2-Diphenylethene (24a)⁹



¹H NMR (500 MHz, CDCl₃): 7.30-7.20 (m, 10H), 6.63 (s, 1H); ¹³C NMR (125 MHz, CDCl₃): 137.3, 130.3, 128.9, 128.2, 127.1.

(Z)-Hex-1-en-1-ylbenzene (25a)²²



¹H NMR (300 MHz, CDCl₃): 7.38-7.20 (m, 5H), 6.43 (d, J = 11.5 Hz, 1H), 5.68 (td, $J_1 = 11.5$ Hz, $J_2 = 6.5$ Hz, 1H), 2.40-2.32 (m, 2H), 1.50-1.32 (m, 4H), 0.91 (t, J = 7.5 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): 137.8, 133.2, 128.7, 128.6, 128.1, 126.4, 32.1, 28.3, 22.4, 14.0.

5-Ethynyl-2-methoxyphenol (30)²³



¹H NMR (500 MHz, CDCl₃): 7.05 (d, J = 2.0 Hz, 1H), 7.03 (dd, $J_1 = 8.5$ Hz, $J_2 = 2.0$ Hz, 1H), 6.78 (d, J = 8.5 Hz, 1H), 5.62 (br s, 1H, -OH), 3.89 (s, 3H), 2.97 (s, 1H); ¹³C NMR (125 MHz, CDCl₃): 147.3, 145.2, 124.8, 118.0, 114.8, 110.4, 83.5, 75.6, 55.9.

2-Methoxy-5-((3,4,5-trimethoxyphenyl)ethynyl)phenol (31)²⁴



¹H NMR (500 MHz, CDCl₃): 7.09 (d, J = 2.0 Hz, 1H), 7.06 (dd, $J_1 = 8.5$ Hz, $J_2 = 2.0$ Hz, 1H), 6.82 (d, J = 8.5 Hz, 1H), 6.75 (s, 2H), 5.60 (br s, 1H, -OH), 3.91 (s, 3H), 3.88 (s, 6H), 3.87 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): 153.0, 147.0, 145.3, 138.6, 124.2, 118.5, 117.5, 116.0, 110.5, 108.7, 88.4, 87.9, 61.0, 56.1, 55.9.

(Z)-2-Methoxy-5-(3,4,5-trimethoxystyryl)phenol (Compretastatin A-4, 32)²⁴



¹H NMR (300 MHz, CDCl₃): 6.92 (d, J = 2.0 Hz, 1H), 6.80 (dd, $J_1 = 8.5$ Hz, $J_2 = 2.0$ Hz, 1H), 6.73 (d, J = 8.5 Hz, 1H), 6.53 (s, 2H), 6.47 (d, J = 11.5 Hz, 1H), 6.41 (d, J = 11.5 Hz, 1H), 5.50 (br s, 1H, -OH), 3.87 (s, 3H), 3.84 (s, 3H), 3.70 (s, 6H); ¹³C NMR (75 MHz, 1H), 5.50 (br s, 1H, -OH), 3.87 (s, 2H), 5.84 (s, 2H), 5.70 (s, 6H); ¹³C NMR (75 MHz), 5.87 (s, 2H), 5.84 (s, 2H), 5.84 (s, 2H), 5.87 (s, 2H), 5.84 (s, 2H), 5.80 (s, 6H); ¹³C NMR (75 MHz), 5.80 (s, 2H), 5.80 (s, 2H), 5.87 (s, 2H), 5.84 (s, 2H), 5.80 (s, 6H); ¹³C NMR (75 MHz), 5.80 (s, 2H), 5.80

CDCl₃): 152.9, 145.7, 145.2, 137.1, 132.7, 130.6, 129.5, 129.0, 121.1, 115.0, 110.3, 106.0, 60.9, 55.9, 55.9.

References

- 1. H. Gryparis and M. Stratakis, *Org. Lett.*, 2014, 16, 1430.
- 2. H. Takiguchi, K. Ohmori and K. Suzuki, Angew. Chem., Int. Ed., 2013, 52, 10472.
- 3. B. M. Trost, A. F. Indolese, T. J. J. Muller and B. Treptow, J. Am. Chem. Soc., 1995, 117, 615.
- 4. J. H. Ahn, M. J. Joung and N. M. Yoon, J. Org. Chem., 1995, 60, 6173.
- 5. V. Gudla and R. Balamurugan, J. Org. Chem., 2011, 76, 9919.
- 6. Q.-W. Song, B. Yu, X.-D. Li, R. Ma, Z.-F. Diao, R.-G. Li, W. Li and L.-N. He, *Green Chem.*, 2014, 16, 1633.
- 7. R. Manikandan and M. Jeganmohan, Org. Lett., 2014, 16, 652.
- T. Wakamatsu, K. Nagao, H. Ohmiya and M. Sawamura, *Angew. Chem., Int. Ed.*, 2013, 52, 11620.
- 9. Commercially available compound.
- 10. C. A. Faler and M. M. Joullie, Org. Lett., 2007, 9, 1987.
- 11. X. Zong, Q.-Z. Zheng and N. Jiao, Org. Biomol. Chem., 2014, 12, 1198.
- 12. L. T. Kliman, S. N. Mlynarski and J. P. Morken, J. Am. Chem. Soc., 2009, 131, 13210.
- 12. M. Mewald, R. Frohlich and M. Oestreich, *Chem. Eur. J.*, 2011, 17, 9406.
- H. Ito, S. Ito, Y. Sasaki, K. Matsuura and M. Sawamura, J. Am. Chem. Soc., 2007, 129, 14856.
- 14. B. M. Trost and M. Lautens, J. Am. Chem. Soc., 1987, 109, 1469.
- 15. K. Singh, S. J. Staig and J. D. Weaver, J. Am. Chem. Soc., 2014, 136, 5275.
- 16. Z.-Q. Liu, L. Sun, J.-G. Wang, J. Han, Y.-K. Zhao and B. Zhou, *Org. Lett.*, 2009, 11, 1437.
- S. K. Murphy, D. A. Petrone, M. M. Coulter and V. M. Dong, *Org. Lett.*, 2011, 13, 6216.
- O. Cusso, I. Garcia-Bosch, D. Font, X. Ribas, J. Lloret-Fillol and M. Costas, Org. Lett., 2013, 15, 6158.
- **19.** P. R. Blakemore, D. K. H. Hoa and W. M. Napa, *Org. Biomol. Chem.*, 2005, **3**, 1365.
- **20.** J.-E. Lee, J. Kwon and J. Yun, *Chem. Commun.*, 2008, 733.

- 21. S. Kojima, T. Fukuzaki, A. Yamakawa and Y. Murai, Org. Lett., 2004, 6, 3917.
- 22. G.-P. Lu, K. R. Voigtritter, C. Caib and B. H. Lipshutz, *Chem. Commun.*, 2012, 48, 8661.
- 23. C. M. Ahn, W.-S. Shin, H. B. Woo, S. Lee and H.-W. Lee, *Bioorg. Med. Chem. Lett.*, 2004, 14, 3893.
- N. J. Lawrence, F. A. Ghani, L. A. Hepworth, J. A. Hadfield, A. T. McGown and R. G. Pritchard, *Synthesis*, 1999, 1656.









*: Absorptions from fully protonated 1a, as starting material 1-D had 93% deuterium content.



Region of the ¹H NMR spectrum from the crude reaction mixture in the Au/TiO₂-catalyzed reaction of alkyne **1** with ammonia borane in THF/D₂O, showing the presence of fully protonated product **a** and deuterated **b** (red)and **c** (blue). Non labelled by arrow absorptions correspond to fully protonated **a**.



The current integrals appear based on the integration of the two aromatic protons set as 2.0. Based the above integrals, a relative ratio $1a/1b/1c \sim 36/43/21$ is calculated.

































































































